Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-EB-FAPI in mRAIR-TC
NCT05410821Phase 1Completed
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DOTA-EB-FAPI in thyroid cancer (3 cohorts), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Incidence of treatment-related adverse events and Maximum Tolerated Dose. Started Jun 2022; status: completed.
02
Drugs
177Lu-DOTA-EB-FAPI
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT05410821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410821.